Early initiation of SGLT2 inhibitors with guideline-directed medical therapy improves LVEF and preserves renal function in newly diagnosed heart failure patients.
Does early initiation of an SGLT2i within guideline-directed medical therapy improve the implementation of quadruple therapy and clinical outcomes in newly diagnosed HFrEF patients?
Initiating GDMT with an SGLT2i in newly diagnosed HFrEF patients facilitates the early implementation of quadruple therapy, improves LVEF, and preserves renal function.
Absolute Event Rate: 0% vs 0%
Initiating GDMT with an SGLT2i facilitates the early implementation of quadruple therapy, improves LVEF, preserves renal function, and shows a trend toward reducing HF decompensations. SGLT2i initiation also demonstrated a favourable safety profile, supporting their early use in newly diagnosed HFrEF patients.
Esteban-Fernández et al. (Mon,) reported a other. Early initiation of SGLT2 inhibitors with guideline-directed medical therapy improves LVEF and preserves renal function in newly diagnosed heart failure patients.